Replies to post #193384 on PCT Ltd (PCTL)

[MrBiocide]

As stated before - this is history - way back earlier this year.....
To date we do not know that PCTL's HOCL was finally tested
On pages 46 to 47 of that meeting NHS Trust report it is clear the managing Board needs a lot more data and proof before adoption - quoting this paragraph ..... "The Chair confirmed a full business case would be presented to the Board based on ICP evidence, cost improvement, performance of solution and sustainability benefits considered with the governors kept in touch on progress" .....which means the North Tees NHS Trust will continue to use its present disinfection products until it is proven that HOCL is sustainable, performs and is cost-effective and as we all know, PCTL's HOCL is very short longevity therefore it is highly probable NTH Solutions have changed to a more effective longer-term HOCL for this critical trial, then add the fact that this meeting report confirms that HOCL is not generally used by UK NHS which means even if NTH Solutions deliver a rock solid report and Business Case to their NHS Trust Board, it will take months to see general adoption by that single NHS Board and Trust, and even longer to convince any other UK NHS Trust to drop present products and move to NTH's HOCL, or another competitors.
At that same 20th September NCC Conference competitors like Methis Health and Hibrisan are Sponsors and will have booths selling their products, Methis having a far better quality HOCL than PCTL's.
Trying to sell to the wider UK NHS is going to be very hard and will take well into 2023, 2024 onwards. No quick gains.
Then add the fact that once that University HOCL effectiveness report arrives it also confirms the generic attributes of any other HOCL around 500ppm which opens the door to numerous HOCL competitors like Methis Health and others using that same generic HOCL @ 500ppm efficacy data.
There is nothing special about HOCL as others make as-good-as or even better.

Ultimately that North Tees Board statement above (Pages 46-47) is what governs adoption policy everywhere in the UK NHS system.of 219 Trusts.
Not all will move to HOCL.
Take-up maybe as low as 10% over five years marketing.

Even if 10% adopted that is 21 UK NHS trusts that may or may not buy a PCTL's machine therefore gross revenues are poor over time, plus other make far better machines.
It is no big-deal to secure UK NHS adoption in fiscal terms as this is a highly competitive market in both EU and UK.